APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihemophilic Factor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antihemophilic Factor Drug Industry Growth and Trends Forecast to 2032

20 December 2025104 pages

Choose your research edition.

Industry ResearchAntihemophilic Factor Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihemophilic Factor Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antihemophilic Factor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihemophilic Factor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihemophilic Factor Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antihemophilic Factor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antihemophilic Factor Drug include Cigna, CSL Behring, GC Pharma, Grifols, Octapharma, Bayer, Hualan Biological Engineering, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antihemophilic Factor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antihemophilic Factor Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antihemophilic Factor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antihemophilic Factor Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antihemophilic Factor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antihemophilic Factor Drug Market by Company

Cigna

CSL Behring

GC Pharma

Grifols

Octapharma

Bayer

Hualan Biological Engineering

Pfizer

Novo Nordisk

Sanofi

Shanghai RAAS blood products

Takeda

Antihemophilic Factor Drug Segment by Type

250 IU

500 IU

1000 IU

1500 IU

2000 IU

3000 IU

4000 IU

Other potencies

Antihemophilic Factor Drug Segment by Application

Adult

Pediatric

Antihemophilic Factor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemophilic Factor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihemophilic Factor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemophilic Factor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antihemophilic Factor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 250 IU Table 2. Major Company of 500 IU Table 3. Major Company of 1000 IU Table 4. Major Company of 1500 IU Table 5. Major Company of 2000 IU Table 6. Major Company of 3000 IU Table 7. Major Company of 4000 IU Table 8. Major Company of Other potencies Table 9. Global Antihemophilic Factor Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 11. Global Antihemophilic Factor Drug Sales Market Share in Volume by Type (2021-2026) Table 12. Global Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 13. Global Antihemophilic Factor Drug Sales Market Share in Value by Type (2021-2026) Table 14. Global Antihemophilic Factor Drug Price by Type (2021-2026) & (US$/Unit) Table 15. Global Antihemophilic Factor Drug Sales by Type (2027-2032) & (W Units) Table 16. Global Antihemophilic Factor Drug Sales Market Share in Volume by Type (2027-2032) Table 17. Global Antihemophilic Factor Drug Sales by Type (2027-2032) & (US$ Million) Table 18. Global Antihemophilic Factor Drug Sales Market Share in Value by Type (2027-2032) Table 19. Global Antihemophilic Factor Drug Price by Type (2027-2032) & (US$/Unit) Table 20. North America Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 21. North America Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Europe Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 23. Europe Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 25. Asia-Pacific Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 27. Latin America Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 29. Middle East and Africa Antihemophilic Factor Drug Sales by Type (2021-2026) & (US$ Million) Table 30. Antihemophilic Factor Drug Industry Trends Table 31. Antihemophilic Factor Drug Industry Drivers Table 32. Antihemophilic Factor Drug Industry Opportunities and Challenges Table 33. Antihemophilic Factor Drug Industry Restraints Table 34. Global Antihemophilic Factor Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global Antihemophilic Factor Drug Revenue Market Share by Company (2021-2026) Table 36. Global Antihemophilic Factor Drug Sales by Company (2021-2026) & (W Units) Table 37. Global Antihemophilic Factor Drug Sales Share by Company (2021-2026) Table 38. Global Antihemophilic Factor Drug Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global Antihemophilic Factor Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global Antihemophilic Factor Drug Major Company Production Sites and Headquarters Table 41. Global Antihemophilic Factor Drug Company, Product Type & Application Table 42. Global Antihemophilic Factor Drug Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global Antihemophilic Factor Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global Antihemophilic Factor Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Antihemophilic Factor Drug Sales Market Share in Volume by Region (2021-2026) Table 48. Global Antihemophilic Factor Drug Sales by Region (2021-2026) & (US$ Million) Table 49. Global Antihemophilic Factor Drug Sales Market Share in Value by Region (2021-2026) Table 50. Global Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global Antihemophilic Factor Drug Sales by Region (2027-2032) & (W Units) Table 52. Global Antihemophilic Factor Drug Sales Market Share in Volume by Region (2027-2032) Table 53. Global Antihemophilic Factor Drug Sales by Region (2027-2032) & (US$ Million) Table 54. Global Antihemophilic Factor Drug Sales Market Share in Value by Region (2027-2032) Table 55. Global Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global Antihemophilic Factor Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 58. Global Antihemophilic Factor Drug Sales Market Share in Volume by Application (2021-2026) Table 59. Global Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 60. Global Antihemophilic Factor Drug Sales Market Share in Value by Application (2021-2026) Table 61. Global Antihemophilic Factor Drug Price by Application (2021-2026) & (US$/Unit) Table 62. Global Antihemophilic Factor Drug Sales by Application (2027-2032) & (W Units) Table 63. Global Antihemophilic Factor Drug Sales Market Share in Volume by Application (2027-2032) Table 64. Global Antihemophilic Factor Drug Sales by Application (2027-2032) & (US$ Million) Table 65. Global Antihemophilic Factor Drug Sales Market Share in Value by Application (2027-2032) Table 66. Global Antihemophilic Factor Drug Price by Application (2027-2032) & (US$/Unit) Table 67. North America Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 68. North America Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Europe Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 70. Europe Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 72. Asia-Pacific Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 74. Latin America Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 76. Middle East and Africa Antihemophilic Factor Drug Sales by Application (2021-2026) & (US$ Million) Table 77. Cigna Company Information Table 78. Cigna Business Overview Table 79. Cigna Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Cigna Antihemophilic Factor Drug Product Portfolio Table 81. Cigna Recent Development Table 82. CSL Behring Company Information Table 83. CSL Behring Business Overview Table 84. CSL Behring Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. CSL Behring Antihemophilic Factor Drug Product Portfolio Table 86. CSL Behring Recent Development Table 87. GC Pharma Company Information Table 88. GC Pharma Business Overview Table 89. GC Pharma Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. GC Pharma Antihemophilic Factor Drug Product Portfolio Table 91. GC Pharma Recent Development Table 92. Grifols Company Information Table 93. Grifols Business Overview Table 94. Grifols Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Grifols Antihemophilic Factor Drug Product Portfolio Table 96. Grifols Recent Development Table 97. Octapharma Company Information Table 98. Octapharma Business Overview Table 99. Octapharma Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Octapharma Antihemophilic Factor Drug Product Portfolio Table 101. Octapharma Recent Development Table 102. Bayer Company Information Table 103. Bayer Business Overview Table 104. Bayer Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Bayer Antihemophilic Factor Drug Product Portfolio Table 106. Bayer Recent Development Table 107. Hualan Biological Engineering Company Information Table 108. Hualan Biological Engineering Business Overview Table 109. Hualan Biological Engineering Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio Table 111. Hualan Biological Engineering Recent Development Table 112. Pfizer Company Information Table 113. Pfizer Business Overview Table 114. Pfizer Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Pfizer Antihemophilic Factor Drug Product Portfolio Table 116. Pfizer Recent Development Table 117. Novo Nordisk Company Information Table 118. Novo Nordisk Business Overview Table 119. Novo Nordisk Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novo Nordisk Antihemophilic Factor Drug Product Portfolio Table 121. Novo Nordisk Recent Development Table 122. Sanofi Company Information Table 123. Sanofi Business Overview Table 124. Sanofi Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Sanofi Antihemophilic Factor Drug Product Portfolio Table 126. Sanofi Recent Development Table 127. Shanghai RAAS blood products Company Information Table 128. Shanghai RAAS blood products Business Overview Table 129. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio Table 131. Shanghai RAAS blood products Recent Development Table 132. Takeda Company Information Table 133. Takeda Business Overview Table 134. Takeda Antihemophilic Factor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Takeda Antihemophilic Factor Drug Product Portfolio Table 136. Takeda Recent Development Table 137. North America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 138. North America Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 139. North America Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 140. North America Antihemophilic Factor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 141. North America Antihemophilic Factor Drug Sales Market Share Forecast by Country (2027-2032) Table 142. North America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. North America Antihemophilic Factor Drug Market Size by Country (2021-2026) & (US$ Million) Table 144. North America Antihemophilic Factor Drug Market Share by Country (2021-2026) Table 145. North America Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. North America Antihemophilic Factor Drug Market Share Forecast by Country (2027-2032) Table 147. Europe Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 148. Europe Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 149. Europe Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 150. Europe Antihemophilic Factor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 151. Europe Antihemophilic Factor Drug Sales Market Share Forecast by Country (2027-2032) Table 152. Europe Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Europe Antihemophilic Factor Drug Market Size by Country (2021-2026) & (US$ Million) Table 154. Europe Antihemophilic Factor Drug Market Share by Country (2021-2026) Table 155. Europe Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Europe Antihemophilic Factor Drug Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 159. Asia-Pacific Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 160. Asia-Pacific Antihemophilic Factor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 161. Asia-Pacific Antihemophilic Factor Drug Sales Market Share Forecast by Country (2027-2032) Table 162. Asia-Pacific Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Asia-Pacific Antihemophilic Factor Drug Market Size by Country (2021-2026) & (US$ Million) Table 164. Asia-Pacific Antihemophilic Factor Drug Market Share by Country (2021-2026) Table 165. Asia-Pacific Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Asia-Pacific Antihemophilic Factor Drug Market Share Forecast by Country (2027-2032) Table 167. Latin America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 168. Latin America Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 169. Latin America Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 170. Latin America Antihemophilic Factor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 171. Latin America Antihemophilic Factor Drug Sales Market Share Forecast by Country (2027-2032) Table 172. Latin America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Latin America Antihemophilic Factor Drug Market Size by Country (2021-2026) & (US$ Million) Table 174. Latin America Antihemophilic Factor Drug Market Share by Country (2021-2026) Table 175. Latin America Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Latin America Antihemophilic Factor Drug Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 179. Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 180. Middle East and Africa Antihemophilic Factor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 181. Middle East and Africa Antihemophilic Factor Drug Sales Market Share Forecast by Country (2027-2032) Table 182. Middle East and Africa Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Middle East and Africa Antihemophilic Factor Drug Market Size by Country (2021-2026) & (US$ Million) Table 184. Middle East and Africa Antihemophilic Factor Drug Market Share by Country (2021-2026) Table 185. Middle East and Africa Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Middle East and Africa Antihemophilic Factor Drug Market Share Forecast by Country (2027-2032) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Antihemophilic Factor Drug Distributors List Table 190. Antihemophilic Factor Drug Customers List Table 191. Research Programs/Design for This Report Table 192. Authors List of This Report Table 193. Secondary Sources Table 194. Primary Sources List of Figures Figure 1. Antihemophilic Factor Drug Image Figure 2. Global Antihemophilic Factor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihemophilic Factor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihemophilic Factor Drug Sales (2021-2032) & (W Units) Figure 5. 250 IU Image Figure 6. Global 250 IU Sales YoY Growth (2021-2032) & (W Units) Figure 7. 500 IU Image Figure 8. Global 500 IU Sales YoY Growth (2021-2032) & (W Units) Figure 9. 1000 IU Image Figure 10. Global 1000 IU Sales YoY Growth (2021-2032) & (W Units) Figure 11. 1500 IU Image Figure 12. Global 1500 IU Sales YoY Growth (2021-2032) & (W Units) Figure 13. 2000 IU Image Figure 14. Global 2000 IU Sales YoY Growth (2021-2032) & (W Units) Figure 15. 3000 IU Image Figure 16. Global 3000 IU Sales YoY Growth (2021-2032) & (W Units) Figure 17. 4000 IU Image Figure 18. Global 4000 IU Sales YoY Growth (2021-2032) & (W Units) Figure 19. Other potencies Image Figure 20. Global Other potencies Sales YoY Growth (2021-2032) & (W Units) Figure 21. Global Antihemophilic Factor Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global Antihemophilic Factor Drug Market Share by Type 2025 VS 2032 Figure 23. North America Antihemophilic Factor Drug Sales Market Share in Volume by Type in 2025 Figure 24. North America Antihemophilic Factor Drug Sales Market Share in Value by Type in 2025 Figure 25. Europe Antihemophilic Factor Drug Sales Market Share in Volume by Type in 2025 Figure 26. Europe Antihemophilic Factor Drug Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific Antihemophilic Factor Drug Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific Antihemophilic Factor Drug Sales Market Share in Value by Type in 2025 Figure 29. Latin America Antihemophilic Factor Drug Sales Market Share in Volume by Type in 2025 Figure 30. Latin America Antihemophilic Factor Drug Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa Antihemophilic Factor Drug Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa Antihemophilic Factor Drug Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 Antihemophilic Factor Drug Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Adult Image Figure 36. Global Adult Sales YoY Growth (2021-2032) & (W Units) Figure 37. Pediatric Image Figure 38. Global Pediatric Sales YoY Growth (2021-2032) & (W Units) Figure 39. Global Antihemophilic Factor Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Antihemophilic Factor Drug Market Share by Application 2025 VS 2032 Figure 41. North America Antihemophilic Factor Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Antihemophilic Factor Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Antihemophilic Factor Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Antihemophilic Factor Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Antihemophilic Factor Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Antihemophilic Factor Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Antihemophilic Factor Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Antihemophilic Factor Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Antihemophilic Factor Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Antihemophilic Factor Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. North America Antihemophilic Factor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Antihemophilic Factor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Antihemophilic Factor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Europe Antihemophilic Factor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Antihemophilic Factor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Antihemophilic Factor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Asia-Pacific Antihemophilic Factor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Antihemophilic Factor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Antihemophilic Factor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Latin America Antihemophilic Factor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Antihemophilic Factor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Antihemophilic Factor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 68. Middle East and Africa Antihemophilic Factor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Antihemophilic Factor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Antihemophilic Factor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Antihemophilic Factor Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Antihemophilic Factor Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies
Applications
  • Adult
  • Pediatric
Companies covered
  • Cigna
  • CSL Behring
  • GC Pharma
  • Grifols
  • Octapharma
  • Bayer
  • Hualan Biological Engineering
  • Pfizer
  • Novo Nordisk
  • Sanofi
  • Shanghai RAAS blood products
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antihemophilic Factor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antihemophilic Factor Drug Market by Type
  6. 1.3.1 250 IU
  7. 1.3.2 500 IU
  8. 1.3.3 1000 IU
  9. 1.3.4 1500 IU
  10. 1.3.5 2000 IU
  11. 1.3.6 3000 IU
  12. 1.3.7 4000 IU
  13. 1.3.8 Other potencies
  14. 1.4 Global Antihemophilic Factor Drug Market Size by Type
  15. 1.4.1 Global Antihemophilic Factor Drug Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global Antihemophilic Factor Drug Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global Antihemophilic Factor Drug Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America Antihemophilic Factor Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe Antihemophilic Factor Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific Antihemophilic Factor Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America Antihemophilic Factor Drug Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa Antihemophilic Factor Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antihemophilic Factor Drug Industry Trends
  2. 2.2 Antihemophilic Factor Drug Industry Drivers
  3. 2.3 Antihemophilic Factor Drug Industry Opportunities and Challenges
  4. 2.4 Antihemophilic Factor Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antihemophilic Factor Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Antihemophilic Factor Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Antihemophilic Factor Drug Price (2021-2026)
  4. 3.4 Global Antihemophilic Factor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antihemophilic Factor Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Antihemophilic Factor Drug Company, Product Type & Application
  7. 3.7 Global Antihemophilic Factor Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antihemophilic Factor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antihemophilic Factor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antihemophilic Factor Drug Tier 1, Tier 2, and Tier 3
4 Antihemophilic Factor Drug Regional Status and Outlook
  1. 4.1 Global Antihemophilic Factor Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antihemophilic Factor Drug Historic Market Size by Region
  3. 4.2.1 Global Antihemophilic Factor Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antihemophilic Factor Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antihemophilic Factor Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antihemophilic Factor Drug Forecasted Market Size by Region
  7. 4.3.1 Global Antihemophilic Factor Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antihemophilic Factor Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antihemophilic Factor Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antihemophilic Factor Drug by Application
  1. 5.1 Antihemophilic Factor Drug Market by Application
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Antihemophilic Factor Drug Market Size by Application
  5. 5.2.1 Global Antihemophilic Factor Drug Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Antihemophilic Factor Drug Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Antihemophilic Factor Drug Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Antihemophilic Factor Drug Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Antihemophilic Factor Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Antihemophilic Factor Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Antihemophilic Factor Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Antihemophilic Factor Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Cigna
  2. 6.1.1 Cigna Company Information
  3. 6.1.2 Cigna Business Overview
  4. 6.1.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Cigna Antihemophilic Factor Drug Product Portfolio
  6. 6.1.5 Cigna Recent Developments
  7. 6.2 CSL Behring
  8. 6.2.1 CSL Behring Company Information
  9. 6.2.2 CSL Behring Business Overview
  10. 6.2.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
  12. 6.2.5 CSL Behring Recent Developments
  13. 6.3 GC Pharma
  14. 6.3.1 GC Pharma Company Information
  15. 6.3.2 GC Pharma Business Overview
  16. 6.3.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
  18. 6.3.5 GC Pharma Recent Developments
  19. 6.4 Grifols
  20. 6.4.1 Grifols Company Information
  21. 6.4.2 Grifols Business Overview
  22. 6.4.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Grifols Antihemophilic Factor Drug Product Portfolio
  24. 6.4.5 Grifols Recent Developments
  25. 6.5 Octapharma
  26. 6.5.1 Octapharma Company Information
  27. 6.5.2 Octapharma Business Overview
  28. 6.5.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Octapharma Antihemophilic Factor Drug Product Portfolio
  30. 6.5.5 Octapharma Recent Developments
  31. 6.6 Bayer
  32. 6.6.1 Bayer Company Information
  33. 6.6.2 Bayer Business Overview
  34. 6.6.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bayer Antihemophilic Factor Drug Product Portfolio
  36. 6.6.5 Bayer Recent Developments
  37. 6.7 Hualan Biological Engineering
  38. 6.7.1 Hualan Biological Engineering Company Information
  39. 6.7.2 Hualan Biological Engineering Business Overview
  40. 6.7.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
  42. 6.7.5 Hualan Biological Engineering Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Antihemophilic Factor Drug Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Novo Nordisk
  50. 6.9.1 Novo Nordisk Company Information
  51. 6.9.2 Novo Nordisk Business Overview
  52. 6.9.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
  54. 6.9.5 Novo Nordisk Recent Developments
  55. 6.10 Sanofi
  56. 6.10.1 Sanofi Company Information
  57. 6.10.2 Sanofi Business Overview
  58. 6.10.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sanofi Antihemophilic Factor Drug Product Portfolio
  60. 6.10.5 Sanofi Recent Developments
  61. 6.11 Shanghai RAAS blood products
  62. 6.11.1 Shanghai RAAS blood products Company Information
  63. 6.11.2 Shanghai RAAS blood products Business Overview
  64. 6.11.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
  66. 6.11.5 Shanghai RAAS blood products Recent Developments
  67. 6.12 Takeda
  68. 6.12.1 Takeda Company Information
  69. 6.12.2 Takeda Business Overview
  70. 6.12.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Takeda Antihemophilic Factor Drug Product Portfolio
  72. 6.12.5 Takeda Recent Developments
7 North America by Country
  1. 7.1 North America Antihemophilic Factor Drug Sales by Country
  2. 7.1.1 North America Antihemophilic Factor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antihemophilic Factor Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Antihemophilic Factor Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antihemophilic Factor Drug Market Size by Country
  6. 7.2.1 North America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antihemophilic Factor Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antihemophilic Factor Drug Sales by Country
  2. 8.1.1 Europe Antihemophilic Factor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antihemophilic Factor Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Antihemophilic Factor Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antihemophilic Factor Drug Market Size by Country
  6. 8.2.1 Europe Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antihemophilic Factor Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antihemophilic Factor Drug Sales by Country
  2. 9.1.1 Asia-Pacific Antihemophilic Factor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antihemophilic Factor Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antihemophilic Factor Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antihemophilic Factor Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antihemophilic Factor Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antihemophilic Factor Drug Sales by Country
  2. 10.1.1 South America Antihemophilic Factor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antihemophilic Factor Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Antihemophilic Factor Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antihemophilic Factor Drug Market Size by Country
  6. 10.2.1 South America Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antihemophilic Factor Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antihemophilic Factor Drug Sales by Country
  2. 11.1.1 Middle East and Africa Antihemophilic Factor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antihemophilic Factor Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antihemophilic Factor Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antihemophilic Factor Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antihemophilic Factor Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antihemophilic Factor Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antihemophilic Factor Drug Value Chain Analysis
  2. 12.1.1 Antihemophilic Factor Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antihemophilic Factor Drug Production Mode & Process
  7. 12.2 Antihemophilic Factor Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antihemophilic Factor Drug Distributors
  10. 12.2.3 Antihemophilic Factor Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst